![]()
Michael R. Dzwonczyk
For over 30 years, Michael has successfully represented multinational companies as lead counsel in trials and appeals of patent cases in District Courts and at the Federal Circuit, as well as Section 337 cases at the International Trade Commission. His experience has encompassed technical areas that include recombinantly produced hormones, pharmaceuticals, protein synthesis and expression products, fibers, films, polymers, plastics and medical devices. Michael also counsels clients on intellectual property issues, including validity and infringement of intellectual property rights, licensing and contract matters and Hatch-Waxman issues.
He has lectured on numerous topics including strategies for opinion drafting, pharmaceutical litigation strategies, AIA procedures, compulsory licensing, and Patent Law Reform. He is the former Chair of FCBA's amicus committee, a former member of its Board of Directors, as well as a former Chair of the AIPLA Chemical Practice Committee. Prior to working as a patent attorney, Michael worked at FMC Corporation agricultural chemicals research facility on the synthesis, isolation and characterization of novel plant growth regulators, herbicides and insecticides.
Michael is a former adjunct professor of law at George Washington University's National Law Center, where he co-taught International and Comparative Patent Law. He is on the Advisory Board of the Naples Roundtable and a regular speaker at the Annual Leahy Institute of Advanced Patent Studies. He has been quoted by The Washington Post, The Legal Times, The Corporate Legal Times, Bloomberg News Service, The IP Law Bulletin, and others.
He has been named in the IAM Patent 1000 list of The World’s Leading Patent Practitioners from 2014-2018, and listed as a leading expert in the Financier Worldwide Corporate Advisor Handbook for Intellectual Property from 2014-2018.
Education
- Dickinson School of Law (J.D.)
- Temple University (B.S.)
- Chemistry
Bar Admissions
- Supreme Court of the United States
- U.S. Court of Appeals - Federal Circuit
- U.S. District Court – Eastern District of Texas
- U.S. District Court - Southern District of Georgia
- U.S. District Court - District of Columbia
- U.S. District Court – Western District of Michigan
- Supreme Court of Pennsylvania
- U.S. Patent and Trademark Office
Memberships
- The Naples Rountable - Advisory Board, Scholarship Committee
- Federal Circuit Bar Association - Board of Directors (Former)
- American Intellectual Property Law Association - Chemical Practice Committee, Chair (Former)
- University of Akron School of Law - IP Advisory Council
- Penn State University, Dickinson School of Law, Health, Science and Policy Advisory Council
Experience
- Laser Spallation Technologies LLC v. The Boeing Company 2:23-cv-02294-AB-SK (CACD 2023)
- Ingenus Pharmaceuticals, LLC et al. v. Accord Healthcare, Inc. C.A. No. 23-377-JLH (DED 2023)
- Ingenus Pharmaceuticals, LLC et al. v. Nevakar Injectibles, Inc. et al. C.A. No. 3:22-cv-07603-MAS-JBD (NJD 2022)
- Ingenus Pharmaceuticals, LLC et al. v. Nexus Pharmaceuticals, Inc. No. 22-cv-02868 (MMR) (ILND 2022)
- Topia Technology, Inc. v. Box, Inc. et al. 6:21-cv-01372-ADA (TXWD 2021)
- Topia Technology, Inc. v. Dropbox, Inc. et al. 6:21-cv-01373-ADA (TXWD 2021)
- Topia Technology, Inc. v. Egnyte, Inc. C.A. No. 1:21-cv-01821-CJB (DED 2021)
- Shilpa Pharma, Inc. v. Novartis Pharmaceuticals Corp. C.A. No. 21-558-MN (DED 2021)
- Glaston Corp. et al. v. Salem Fabrication Technologies Group, Inc. No. 1:21-cv-00942-TDS-LPA (NCMD 2021)
- Auromedics Pharma et al v. Ingenus Pharmaceuticals 1:20-cv-01235 (DED 2020)
- Allergan Pharm’s. Int’l. Ltd. et al. v. Sun Pharm’s Indst’s. Ltd. et al. No. 2:20-cv-10176-SDW-LDW (NJD 2020)
- Saint Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc. CAFC-18-1638 (CAFC 2018)
- Arjuna Natural Ltd. v. Dolcas Biotech et al. 2-18-cv-11971 (DNJ 2018)
- Hikma Pharm’s. v. Granules Pharm’s. 18-cv-00085 (DED 2018)
- Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. et al CAFC-18-1130 (CAFC 2017)
- Mt. Derm GmbH et al v. 8 Layer Inc. d/b/a Workhorse Irons 1-17-cv-00593 (MIWD 2017)
- Mt. Derm GmbH et al v. Needlejig Tattoo Supply, Inc. 3-17-cv-11294 (MAD 2017)
- Gilead Sciences, Inc. et al v. Amneal Pharmaceuticals LLC 1-17-cv-00943 (DED 2017)
- MT DERM GmbH et al v. Joker Tattoo Supply LLC 1-17-cv-00949 (CAED)
- Forest Laboratories, LLC v. Sigmapharm Laboratories, LLC CAFC-17-2369 (CAFC 2017)
- MT DERM GmbH et al v. Oreladel BH Corp. d/b/a NPM International New-York USA 1-17-cv-06301 (NYED 2017)
- MT DERM GmbH et al v. Bishop Tattoo Supply, Inc. 8-17-cv-01205 (CACD 2017)
- MT. DERM GmbH v. Derma Blush Inc. 2-17-cv-09175 (CACD 2017)
- MT DERM GmbH et al v. Purebeau USA, Inc. 1-17-cv-08328 (NYSD 2017)
- Daiichi Sankyo Company, Ltd. v. Accord Healthcare Inc., USA CAFC-17-1052 (CAFC 2016)
- Cephalon Inc. v. Hetero Labs Limited CAFC-16-2348 (CAFC 2016)
- Shire Pharmaceutical Development Inc. et al v. Amneal Pharmaceuticals LLC et al NJD 1-15-cv-02865 (NJD 2015)
- Forest Labs, Inc.. v. Amneal Pharm. LLC 15-cv-00430-SLR (D. Del. 2015)
- Hospira, Inc. v. Amneal Pharm. LLC Case No. 15-697-RGA (D. Del. 2015)
- Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. et al TXED-2-15-cv-01455 (TXED 2015)
- Novartis Pharmaceuticals Corporation et al v. Amneal Pharmaceuticals LLC et al DED-1-15-cv-01025
- Mt. Derm GmbH et al v. Kingpin Tattoo Supply, Inc. FLMD-8-15-cv-02737 (MD FL 2015)
- Inter Partes Review of U.S. Patent No. 9,248,191 IPR2017-00601
- Inter Partes Review of U.S. Patent No. 8,648,048 IPR2017-00600
- Inter Partes Review of U.S. Patent No. 8,633,162 IPR2017-00599
- Inter Partes Review of U.S. Patent No. 8,642,556 IPR2017-00598
- Inter Partes Review of U.S. Patent No. 8,629,111 IPR2017-00596
- Inter Partes Review of U.S. Patent No. 8,685,930 IPR2017-00594
- Inter Partes Review of U.S. Patent No. 9,266,816 IPR2022-00886
- Inter Partes Review of U.S. Patent No. 8,650,911 IPR2022-01516
- Inter Partes Review of U.S. Patent No. 8,479,540 IPR2022-01517
